

# CITATION REPORT

List of articles citing

**MET and VEGF: synergistic targets in castration-resistant prostate cancer**

**DOI: 10.1007/s12094-011-0719-5**

**Clinical and Translational Oncology, 2011, 13, 703-9.**

**Source:** <https://exaly.com/paper-pdf/51386661/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	Bevacizumab treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1241-9	5.4	14
36	Controlling escape from angiogenesis inhibitors. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 699-709	31.3	192
35	Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. <i>Molecular Medicine</i> , <b>2012</b> , 18, 887-98	6.2	41
34	Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 77-83	3.3	29
33	Cell mates: paracrine and stromal targets for prostate cancer therapy. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 441-51	5.5	28
32	Cabozantinib as a novel therapy for renal cell carcinoma. <i>Current Oncology Reports</i> , <b>2013</b> , 15, 76-82	6.3	45
31	Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. <i>Cancer</i> , <b>2013</b> , 119, 1768-75	6.4	37
30	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 412-9	2.2	365
29	C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. <i>Pathology Research and Practice</i> , <b>2013</b> , 209, 215-20	3.4	8
28	Bevacizumab for glioblastoma-a promising drug or not?. <i>Cancers</i> , <b>2013</b> , 5, 1456-68	6.6	4
27	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2013</b> , 19, 316-23	2.2	42
26	Development of cabozantinib for the treatment of prostate cancer. <i>Core Evidence</i> , <b>2014</b> , 9, 61-7	4.9	4
25	A phase I study of cabozantinib (XL184) in patients with renal cell cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1603-8	10.3	115
24	Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 270-81	7.5	24
23	A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. <i>Thyroid</i> , <b>2014</b> , 24, 1508-14	6.2	57
22	Pao Pereira Extract Suppresses Castration-Resistant Prostate Cancer Cell Growth, Survival, and Invasion Through Inhibition of NFB Signaling. <i>Integrative Cancer Therapies</i> , <b>2014</b> , 13, 249-58	3	8
21	Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 617-30	12.9	69

20	The treatment landscape in thyroid cancer: a focus on cabozantinib. <i>Cancer Management and Research</i> , <b>2015</b> , 7, 265-78	3.6	28
19	The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. <i>Gene Therapy</i> , <b>2015</b> , 22, 247-56	4	67
18	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , <b>2015</b> , 67, 310-8	10.2	32
17	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 2167-72	4.4	15
16	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 160, 305-312	4.4	27
15	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3005-13	2.2	163
14	The association between thyroid volume, L-thyroxine therapy and hepatocyte growth factor levels among patients with euthyroid and hypothyroid goitrous and non-goitrous Hashimoto's thyroiditis versus healthy subjects. <i>Endocrine Research</i> , <b>2016</b> , 41, 110-5	1.9	1
13	The best of both worlds - managing the cancer, saving the bone. <i>Nature Reviews Endocrinology</i> , <b>2016</b> , 12, 29-42	15.2	27
12	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 107-21	12.9	35
11	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 432-440	8.7	43
10	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 229-236	7.5	20
9	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2017</b> , 1, 15-29	0.6	4
8	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 1053	4.2	4
7	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6122-6131	12.9	4
6	The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 69	12.8	1
5	A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	1
4	Targeting molecular aberrations in urothelial carcinoma: are we almost there?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 195-9	7.1	3
3	Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 195-199	7.1	2

- 2 Downregulation of miR-99b-5p and Upregulation of Nuclear mTOR Cooperatively Promotes the Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer. **2022**, 23, 9643 2
- 1 A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. **2022**, 221, 1428-1438 2